About Ansbert Gadicke
Ansbert Gadicke is a 10% owner at Entrada Therapeutics.
Form D filings name Ansbert Gadicke as a director at Reunion Neuroscience and NextPoint Therapeutics.
Ansbert Gadicke reports to the SEC as a director or major shareholder of 47 public companies, including Aktis Oncology (AKTS), Werewolf Therapeutics (HOWL) and iTeos Therapeutics (ITOS).
Ansbert Gadicke first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Ansbert Gadicke in the role, so the role may have started earlier or lasted longer.
EI
Entrada Therapeutics, Inc.
10% owner
2021 – 2026 · Public company (TRDA)
AI
WI
Werewolf Therapeutics, Inc.
10% owner
2021 – 2025 · Public company (HOWL)
II
iTeos Therapeutics, Inc.
Director and 10% owner
2020 – 2025 · Public company (ITOS)
TI
TCR2 Therapeutics Inc.
Director and 10% owner
2019 – 2023 · Public company (TCRR)
CI
Cullinan Therapeutics, Inc.
Director and 10% owner
2021 – 2023 · Public company (CGEM)
NextPoint Therapeutics, Inc.
Director
2022 · Cambridge, MA
Develops targeted cancer treatments for patients with solid tumors.
KI
Kalaris Therapeutics, Inc.
Director and 10% owner
2020 – 2022 · Public company (KLRS)
RI
Repare Therapeutics Inc.
10% owner
2020 – 2021 · Public company (RPTX)
HI
Harpoon Therapeutics, Inc.
10% owner
2019 – 2021 · Public company (HARP)
OI
Oncorus, Inc.
10% owner
2020 · Public company (ONCR)
DI
Dyne Therapeutics, Inc.
10% owner
2020 · Public company (DYN)
RI
Rhythm Pharmaceuticals, Inc.
10% owner
2017 · Public company (RYTM)
RI
Radius Health, Inc.
Director and 10% owner
2008 – 2017 · Public company (RDUS)
CI
Chiasma, Inc.
Director and 10% owner
2015 – 2016 · Public company (CHMA)
SI
Syndax Pharmaceuticals Inc
10% owner
2016 · Public company (SNDX)
AI
Avalo Therapeutics, Inc.
10% owner
2015 · Public company (AVTX)
TI
TriVascular Technologies, Inc.
10% owner
2014 · Public company (TRIV)
AI
Aratana Therapeutics, Inc.
10% owner
2013 – 2014 · Public company (PETX)
EI
Epizyme, Inc.
10% owner
2013 – 2014 · Public company (EPZM)
HI
Histogen Inc.
10% owner
2013 · Public company (HSTO)
PI
Pacira BioSciences, Inc.
10% owner
2011 – 2013 · Public company (PCRX)
HI
Humanigen, Inc.
10% owner
2012 – 2013 · Public company (HGEN)
PI
Pernix Sleep, Inc.
10% owner
2007 – 2012 · Public company (SOMX)
VI
Verastem, Inc.
Director
2012 · Public company (VSTM)
EI
EPIRUS Biopharmaceuticals, Inc.
10% owner
2009 – 2011 · Public company (EPRS)
RI
ReShape Weightloss Inc.
10% owner
2007 – 2010 · Public company (RSLS)
AI
Altimmune, Inc.
10% owner
2007 – 2010 · Public company (ALT)
AI
ARYx Therapeutics, Inc.
10% owner
2007 – 2010 · Public company (ARYX)
SI
Senorx Inc.
10% owner
2007 – 2010 · Public company (SENO)
AI
Aveo Pharmaceuticals, Inc.
10% owner
2010 · Public company (AVEO)
MI
Metabasis Therapeutics Inc.
10% owner
2008 – 2010 · Public company (MBRX)
PI
Peplin Inc.
10% owner
2008 – 2009 · Public company (PLIN)
PI
Poniard Pharmaceuticals, Inc.
10% owner
2006 – 2009 · Public company (PARD)
OC
Oscient Pharmaceuticals Corp.
10% owner
2009 · Public company (OSCI)
MC
Memory Pharmaceuticals Corp.
10% owner
2006 – 2009 · Public company (MEMY)
RI
Restore Medical, Inc.
10% owner
2006 – 2008 · Public company (REST)
PI
Pharmasset Inc
Director and 10% owner
2007 – 2008 · Public company (VRUS)
CI
Cryocor Inc.
10% owner
2007 – 2008 · Public company (CRYO)
VI
Viacell Inc.
10% owner
2007 · Public company (VIAC)
HI
Hemosense Inc.
10% owner
2007 · Public company (HEM)
AC
Alsius Corp
10% owner
2007 · Public company (ALUS)
HC
Helicos Biosciences Corp.
10% owner
2007 · Public company (HLCS)
CI
Cornerstone Therapeutics Inc.
Reporting person
2007 · Public company (CRTX)
CI
Cotherix Inc.
10% owner
2007 · Public company (CTRX)
AI
Affymax Inc.
10% owner
2006 · Public company (AFFY)
OI
Omrix Biopharmaceuticals, Inc.
10% owner
2006 · Public company (OMRI)
AI
Acorda Therapeutics, Inc.
10% owner
2006 · Public company (ACOR)
Key Colleagues at Startups
The people Ansbert Gadicke works with at each company, as listed on that company's latest Form D.
Reunion Neuroscience, Inc. · Form D/A, Sep 9, 2025
GM
Gregory Mayes
Executive officer and director
ME
Michael Ehlers
Director
NS
Natalie Sacks
Director
EL
Ellen Lubman
Director
MP
Mark Pollack
Executive officer
AL
Alon Lazarus
Director
NB
Nathan Bryson
Executive officer
MT
Mark Theeuwes
Executive officer
ES
Edward Smith
Chief Financial Officer
NextPoint Therapeutics, Inc. · Form D, Dec 27, 2022
Paulina Hill
Board Member
Detlev Biniszkiewicz
Chairman of the Board
PC
Paul Conrad
Secretary and Treasurer
MR
Matthew Roden
Director
Rakhshita Dhar
Board Member